CYH
Community Health Systems, Inc.
CYH trails on the overall score without a compensating advantage in the available component scores.
NVO
Novo Nordisk A/S
NVO has the edge over CYH overall, supported by lower modeled downside and stronger modeled upside.
CYH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Weak |
CYH's profitability is currently stable, but its revenue, cash flow and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CYH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1.3x | $0.35 | -84% |
| Fair | 2x | $0.55 | -75% |
| Expensive | 4.4x | $1.18 | -47% |
| Current | 8.2x | $2.21 | — |
Historical ranges are pointers, not guarantees.
CYH's PE is in its expensive range at 8.2x.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over CYH in the historical PE scenario, which offers more potential upside but is not a forecast.
CYH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Stable | |
| Limited | |
| Low |
Analysts expect CYH's losses to grow, with revenue declining. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CYH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.27 | -89% |
| Q2 2026 | $1.86 | +$3.35 |
| Q1 2026 | $3.44 | +$7.12 |
| Q4 2025 | $3.77 | +$7.67 |
| Q3 2025 | $2.42 | +$5.43 |
| Q2 2025 | -$1.49 | -$0.74 |
| Q1 2025 | -$3.68 | -$2.74 |
| Q4 2024 | -$3.90 | -$2.88 |
CYH's earnings per share have fallen from their peak: $0.27 over the past year, against $4.39 in late 2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CYH on earnings, with more consistent year-over-year improvement.
CYH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8B | -11% |
| Q2 2026 | $2.8B | -9.8% |
| Q1 2026 | $3B | -6.1% |
| Q4 2025 | $3.1B | -4.9% |
| Q3 2025 | $3.1B | -0.1% |
| Q2 2025 | $3.1B | -0.2% |
| Q1 2025 | $3.2B | +0.6% |
| Q4 2024 | $3.3B | +2.6% |
CYH's revenue has slid since its 2019 peak: $2.8B last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.3% | -2.6 points |
| Q2 2026 | 14% | -2.6 points |
| Q1 2026 | 9.5% | +0.5 points |
| Q4 2025 | 14% | +6 points |
| Q3 2025 | 7.9% | +15 points |
| Q2 2025 | 16% | +8.8 points |
| Q1 2025 | 9% | +1.6 points |
| Q4 2024 | 8.5% | -1.8 points |
CYH's operating margin was 5.3% last quarter, down 2.6 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CYH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CYH on profitability, with a higher operating margin.
CYH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $67M | +1575% |
| Q2 2026 | $12M | +$15M |
| Q1 2026 | -$373M | -1166% |
| Q4 2025 | $172M | +61% |
| Q3 2025 | $4M | +$7M |
| Q2 2025 | -$3M | -123% |
| Q1 2025 | $35M | +1067% |
| Q4 2024 | $107M | +$127M |
CYH's free cash flow was −$122M over the past year, against $143M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CYH on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -963K shares |
| 1 year | +0.3% | +355K shares |
| 3 years | +3.7% | +4.8M shares |
| 5 years | +3.6% | +4.7M shares |
| Available history | +19% | +21.6M shares |
CYH has 136M diluted shares, about the same as a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CYH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CYH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.5x | High |
| Q2 2026 | 5.2x | High |
| Q1 2026 | 4.9x | High |
| Q4 2025 | 5.3x | High |
| Q3 2025 | 5.9x | High |
| Q2 2025 | 7.9x | High |
| Q1 2025 | 10.2x | High |
| Q4 2024 | 11.1x | High |
CYH's net debt is about 5.5 years of its operating earnings (EBITDA), down from 5.9 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over CYH on leverage, with a lower net debt burden relative to earnings.
CYH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 19.0 | Oversold |
CYH's weekly RSI is 34 (neutral) and its Stochastic is 19 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CYH PE vs Healthcare Sector
| Metric | CYH | Sector median | Relative |
|---|---|---|---|
| PE | 8.2x | 26x | 68% below |
| PE % | 92 | 29 | 63 pts above |
CYH has the edge over NVO on valuation relative to its sector.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CYH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.63 | 16% below |
| 20 week MA | $2.90 | 24% below |
| 50 week MA | $3.03 | 27% below |
| 100 week MA | $3.09 | 28% below |
| 200 week MA | $3.55 | 38% below |
CYH is in a downtrend: it's below all five of its weekly moving averages, and 38% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CYH on trend strength, trading above more of its moving averages.
CYH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.77 | $7.67 | +177% |
| 2021 | $7.67 | $13.3 | +73% |
| 2022 | $13.3 | $3.88 | -71% |
| 2023 | $3.88 | $3.13 | -19% |
| 2024 | $3.13 | $3.03 | -3.2% |
| 2025 | $3.03 | $3.23 | +6.6% |
| 2026 YTD | $3.23 | $2.21 | -32% |
CYH's yearly returns have swung widely, from +177% in 2020 to −71% in 2022. It's down 32% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CYH on returns for 2026, with the stronger performance.